{
  "ticker": "OSL",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02971694",
  "id": "02971694",
  "pages": 2,
  "price_sensitive": true,
  "date": "20250723",
  "time": "0827",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250723/pdf/06m1lcf929cn3b.pdf",
  "summary": "- **Completion of patient recruitment for TRIPP-FFX clinical trial** (target: 88 patients across 15 hospitals).  \n- **Expected data readout in early 2026**\u2014evaluating safety/efficacy of OncoSil\u2122 device combined with FOLFIRINOX chemotherapy for pancreatic cancer.  \n- **Milestone for clinical strategy**, supporting broader adoption of the device.  \n\n*No material financial, capital, or trading-specific information identified.*",
  "usage": {
    "prompt_tokens": 1637,
    "completion_tokens": 95,
    "total_tokens": 1732,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-07-22T22:35:08.820761"
}